Biologics by McKesson Selected as Limited Distribution Specialty Pharmacy Provider for HERNEXEOS® (zongertinib tablets)
Effective July 13, Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) will be supported by Biologics by McKesson as a limited distribution specialty pharmacy partner.
ENSACOVE™ (ensartinib), FDA-Approved Treatment for Adult Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer, Exclusively Available at Biologics by McKesson
Biologics by McKesson became the sole specialty pharmacy provider for ENSACOVE and exclusive hub services provider for adults with advanced ALK-positive non-small cell lung cancer.
AUGTYRO™ (Repotrectinib), FDA Approved for Treatment of AdvancedROS1-Positive & NTRK-Positive NSCLC, Available at Biologics by McKessonSpecialty Pharmacy in Limited Distribution Network
Biologics by McKesson joined the limited distribution network for AUGTYRO, approved for ROS1-positive non-small cell lung cancer and certain NTRK gene fusion-positive solid tumors.
IBTROZI™ (Taletrectinib), FDA-Approved Treatment, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for IBTROZI, a next-generation ROS1 inhibitor for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
EMRELIS™ (telisotuzumab vedotin-tllv), FDA Approved for Treatment of Adult Patients with Previously Treated Non-Small Cell Lung Cancer, Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy provider for EMRELIS, a first-in-class intravenous therapy for previously treated non-squamous NSCLC with high c-Met protein overexpression.